

Richard C Becker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7123015/publications.pdf>

Version: 2024-02-01

171
papers

25,063
citations

50276

46
h-index

6654

156
g-index

176
all docs

176
docs citations

176
times ranked

21556
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	27.0	8,006
2	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	27.0	6,019
3	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833.	27.0	951
4	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	2.8	807
5	The Perioperative Management of Antithrombotic Therapy. <i>Chest</i> , 2008, 133, 299S-339S.	0.8	763
6	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. <i>Lancet</i> , The, 2010, 376, 1320-1328.	13.7	709
7	COVID-19 update: Covid-19-associated coagulopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 54-67.	2.1	529
8	Aptamers as Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 61-79.	9.4	383
9	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2009, 157, 599-605.	2.7	363
10	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
11	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1456-1462.	2.8	339
12	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2011, 32, 2933-2944.	2.2	335
13	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	2.2	266
14	The Primary and Secondary Prevention of Coronary Artery Disease. <i>Chest</i> , 2008, 133, 776S-814S.	0.8	234
15	COVID-19-associated vasculitis and vasculopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 499-511.	2.1	222
16	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	2.8	212
17	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	2.8	181
18	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180

#	ARTICLE	IF	CITATIONS
19	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2271-2281.	2.8	159
20	Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1712-1715.	2.9	156
21	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	2.2	154
22	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016, 133, 352-360.	1.6	141
23	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. <i>Platelets</i> , 2014, 25, 517-525.	2.3	138
24	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. <i>European Heart Journal</i> , 2016, 37, 1325-1333.	2.2	137
25	Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 183-187.	2.1	136
26	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. <i>Circulation</i> , 2016, 134, 37-47.	1.6	134
27	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8.	2.7	128
28	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
29	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016, 387, 349-356.	13.7	109
30	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
31	Beyond Thrombosis. <i>Chest</i> , 2011, 139, 658-668.	0.8	96
32	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2015, 169, 899-905.e1.	2.7	91
33	Association of Blood Pressure Level With Left Ventricular Mass in Adolescents. <i>Hypertension</i> , 2019, 74, 590-596.	2.7	87
34	Anticipating the long-term cardiovascular effects of COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 512-524.	2.1	85
35	Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1669-1678.	2.8	78
36	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 145-152.	4.0	75

#	ARTICLE	IF	CITATIONS
37	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	74
38	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014, 35, 1541-1550.	2.2	70
39	Translational Implications of Platelets as Vascular First Responders. <i>Circulation Research</i> , 2018, 122, 506-522.	4.5	66
40	Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. <i>American Heart Journal</i> , 2020, 227, 91-99.	2.7	60
41	Vascular Smooth Muscle Cells in Aortic Aneurysm: From Genetics to Mechanisms. <i>Journal of the American Heart Association</i> , 2021, 10, e023601.	3.7	60
42	Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 104, 976-983.	3.4	55
43	The pharmacology of novel oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 217-233.	2.1	54
44	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.7	52
45	Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. <i>Molecular Therapy</i> , 2019, 27, 1228-1241.	8.2	52
46	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016, 179, 77-86.	2.7	51
47	Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics. <i>Thrombosis and Haemostasis</i> , 2010, 103, 586-595.	3.4	48
48	Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 177-183.	2.1	46
49	Covid-19 treatment update: follow the scientific evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 43-53.	2.1	45
50	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2261-2276.	2.8	44
51	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1447-1456.	2.9	41
52	The many faces of the contact pathway and their role in thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 9-20.	2.1	40
53	SHIP-AHOY (Study of High Blood Pressure in Pediatrics: Adult Hypertension Onset in Youth). <i>Hypertension</i> , 2018, 72, 625-631.	2.7	40
54	Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. <i>Thrombosis and Haemostasis</i> , 2010, 103, 535-544.	3.4	39

#	ARTICLE	IF	CITATIONS
55	Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor's page series. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 692-707.	2.1	39
56	Inflammation and coronary artery disease. <i>Coronary Artery Disease</i> , 2018, 29, 429-437.	0.7	38
57	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	2.9	36
58	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017, 186, 91-99.	2.7	36
59	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	1.6	36
60	Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. <i>American Journal of Gastroenterology</i> , 2009, 104, 2903-2917.	0.4	35
61	Cell-Based Models of Coagulation: A Paradigm in Evolution. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 20, 65-68.	2.1	32
62	Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 14-26.	2.1	32
63	COVID-19 and its sequelae: a platform for optimal patient care, discovery and training. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 587-594.	2.1	32
64	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
65	Translation and Clinical Development of Antithrombotic Aptamers. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 147-155.	3.6	26
66	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 573-584.	3.2	26
67	Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort. <i>American Heart Journal</i> , 2017, 190, 40-45.	2.7	25
68	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2402-2410.	2.4	25
69	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	1.5	24
70	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016, 177, 1-8.	2.7	23
71	Toward understanding the 2019 Coronavirus and its impact on the heart. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 33-42.	2.1	23
72	Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. <i>Thrombosis Research</i> , 2006, 117, 439-446.	1.7	21

#	ARTICLE	IF	CITATIONS
73	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	2.9	21
74	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 294-302.	2.4	20
75	Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 591-599.	1.8	19
76	Prediction of Ambulatory Hypertension Based on Clinic Blood Pressure Percentile in Adolescents. <i>Hypertension</i> , 2018, 72, 955-961.	2.7	19
77	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 145-153.	2.1	18
78	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017, 40, 390-398.	1.8	16
79	Anticoagulants. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 503-515.	1.7	16
80	Interleukin-18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019, 42, 1202-1209.	1.8	16
81	Rapidly Regulating Platelet Activity In Vivo With an Antidote Controlled Platelet Inhibitor. <i>Molecular Therapy</i> , 2012, 20, 391-397.	8.2	15
82	Inflammatory Response and Thrombosis in Older Individuals. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 669-674.	2.7	15
83	Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. <i>American Heart Journal</i> , 2015, 169, 496-507.e1.	2.7	15
84	Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1-11.	2.1	15
85	Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 883-891.e9.	4.4	14
86	Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 520-526.	1.0	14
87	Understanding the dynamics of thrombin in cardiovascular disease: Pathobiology and biochemistry for the clinician. <i>American Heart Journal</i> , 2005, 149, S2-S8.	2.7	13
88	Factor IXa as a target for anticoagulation in thrombotic disorders and conditions. <i>Drug Discovery Today</i> , 2014, 19, 1445-1453.	6.4	13
89	Reversal of novel oral anticoagulants. <i>Current Opinion in Pharmacology</i> , 2016, 27, 86-91.	3.5	13
90	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001349.	3.7	12

#	ARTICLE	IF	CITATIONS
91	Genetic, clinical, molecular, and pathogenic aspects of the South Asian-specific polymorphic MYBPC3 [†] 25bp variant. <i>Biophysical Reviews</i> , 2020, 12, 1065-1084.	3.2	12
92	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 153-163.	1.0	12
93	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. <i>Thrombosis Research</i> , 2017, 156, 184-190.	1.7	11
94	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. <i>Clinical Cardiology</i> , 2018, 41, 39-45.	1.8	11
95	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 563-569.	2.1	11
96	Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 119-121.	2.1	10
97	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 170, e59-e62.	1.7	10
98	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) <i>Tj ETQq0 0 0 rgrBT /Overlock 10 Tf 5</i> <i>Cardiology</i> , 2017, 120, 1837-1840.	1.6	10
99	COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1010-1019.	2.1	10
100	REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 707-15.	2.8	10
101	Optimizing Heparin Compounds: A Working Construct for Future Antithrombotic Drug Development. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 55-58.	2.1	9
102	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials. <i>American Heart Journal</i> , 2015, 169, 315-322.	2.7	9
103	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2022, 33, 425-431.	2.3	9
104	Novel constructs for thrombin inhibition. <i>American Heart Journal</i> , 2005, 149, S61-S72.	2.7	8
105	Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 146-153.	2.1	8
106	The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 273-278.	2.1	8
107	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
108	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) <i>Tj ETQq0 0 0 rgrBT /Overlock 10 Tf 5</i>	1.6	8

#	ARTICLE	IF	CITATIONS
109	The Importance of Factor Xa Regulatory Pathways in Vascular Thromboresistance: Focus on Protein Z. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 135-137.	2.1	7
110	Antiplatelet Therapy in Acute Coronary Syndrome (ACS): Applying New Science to Clinical Decisions. <i>American Journal of Cardiology</i> , 2010, 106, S2-S3.	1.6	7
111	Structure–function relationships of factor Xa inhibitors: implications for the practicing clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 234-241.	2.1	7
112	Aspirin dosing in cardiovascular disease prevention and management: an update. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 499-511.	2.1	7
113	Editor’s page: fundamentals in neurocardiology. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 74-77.	2.1	6
114	Antidote–Controlled Antithrombotic Therapy Targeting Factor IXa and Von Willebrand Factor. <i>Annals of the New York Academy of Sciences</i> , 2009, 1175, 61-70.	3.8	6
115	Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 493-504.	2.1	6
116	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.	2.7	6
117	Antithrombotic therapy: new areas to understand efficacy and bleeding. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1-8.	3.4	5
118	Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents?. <i>Circulation</i> , 2015, 131, 2010-2019.	1.6	5
119	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020, 293, 35-41.	0.8	5
120	Bridging Anticoagulation with Mechanical Heart Valves: Current Guidelines and Clinical Decisions. <i>Current Cardiology Reports</i> , 2020, 22, 130.	2.9	5
121	Platelet biology for the clinician-scientist: an evolution of understanding. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 235-237.	2.1	4
122	The importance of VTE prevention after orthopaedic surgery. <i>Lancet</i> , The, 2009, 373, 1661-1662.	13.7	4
123	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq1 1 0.784314 rgBj /Overlock	2.7	4
124	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATElet inhibition and patient Outcomes (PLATO) study. <i>Platelets</i> , 2019, 30, 579-588.	2.3	4
125	Factor Xa inhibitors: critical considerations for clinical development and testing. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 397-402.	2.1	4
126	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021, 236, 4-12.	2.7	4

#	ARTICLE	IF	CITATIONS
127	The case for preoperative aspirin administration in patients undergoing elective CABG: is it open or closed?. <i>Annals of Translational Medicine</i> , 2016, 4, S26-S26.	1.7	4
128	Focus on thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 24, 183-222.	2.1	3
129	Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 513-514.	2.1	3
130	Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. <i>Thrombosis Research</i> , 2009, 123, 419-428.	1.7	3
131	Designing Human InÂVitro Models for Drug Development. <i>Journal of the American College of Cardiology</i> , 2020, 75, 587-589.	2.8	3
132	Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy. <i>Cells</i> , 2021, 10, 349.	4.1	3
133	The potential roles of Von Willebrand factor and neutrophil extracellular traps in the natural history of hypertrophic and hypertensive cardiomyopathy. <i>Thrombosis Research</i> , 2020, 192, 78-87.	1.7	3
134	Biosignatures in thrombotic disorders. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 157-158.	2.1	2
135	Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 159-161.	2.1	2
136	Platelets from genome to proteome and beyond. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 245-248.	2.1	2
137	A rationale for conducting parallel mechanistic studies in clinical trials of pharmacotherapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 300-302.	2.1	2
138	Biomarker science: on a theme of personalized medicine. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 141-142.	2.1	2
139	The unmet need for philanthropic funding of early career cardiovascular investigators. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 527-531.	2.1	2
140	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019, 8, 283-295.	2.6	2
141	Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1169-1170.	27.0	2
142	Medical publishing during the COVID-19 pandemic: then and now. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1101-1106.	2.1	2
143	Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. <i>Cell Reports Medicine</i> , 2021, 2, 100299.	6.5	2
144	Factor Xa?Protease Activated Receptor Interface: A Paradigm for Combination Pharmacotherapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 153-155.	2.1	1

#	ARTICLE	IF	CITATIONS
145	Thrombin: Science and application in clinical practice. <i>American Heart Journal</i> , 2005, 149, S1.	2.7	1
146	Atherothrombosis at a distance: Contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues. <i>Thrombosis Research</i> , 2007, 119, 761-768.	1.7	1
147	Coagulopathy and Stroke. , 0, , 152-169.		1
148	A clinical cardiology perspective of thrombophilias. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 378-389.	2.1	1
149	Early-onset obesity and the unwanted promise of thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 125-128.	2.1	1
150	A Freeze on Tailored Antiplatelet Therapy?. <i>Circulation</i> , 2014, 129, 2088-2090.	1.6	1
151	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". <i>Circulation</i> , 2016, 134, e7-8.	1.6	1
152	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 427-429.	3.4	1
153	A legacy of words. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 197-199.	2.1	1
154	Unraveling the Genetic Basis of Recurrent Venous Thromboembolism. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, .	3.6	1
155	The rapid proliferation of solicited content online journals: a quest to disseminate knowledge?. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 337-344.	2.1	1
156	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. <i>Heart Rhythm O2</i> , 2021, 2, 215-222.	1.7	1
157	International COVID-19 biomarkers colloquium. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 983-984.	2.1	1
158	Electronic health record-embedded decision support to reduce stroke risk in patients with atrial fibrillation " Study protocol. <i>American Heart Journal</i> , 2022, 247, 42-54.	2.7	1
159	South Asian-Specific MYBPC3 25bp Deletion Carriers Display Hypercontraction and Impaired Diastolic Function Under Exercise Stress. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 766339.	2.4	1
160	Patient-Specific Antithrombotic Strategies: Lessons Not Yet Learned from the Renal Insufficiency Paradigm. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 215-217.	2.1	0
161	Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease. <i>Circulation</i> , 2008, 118, .	1.6	0
162	Coagulopathy and Stroke. , 0, , 152-169.		0

#	ARTICLE	IF	CITATIONS
163	Biomarker science: direction for the scientific community. Journal of Thrombosis and Thrombolysis, 2009, 27, 355-357.	2.1	0
164	Examining biology and pharmacology-based hypotheses in the PLATO trial. Journal of Thrombosis and Thrombolysis, 2010, 30, 119-120.	2.1	0
165	Response to Letter Regarding Article, "Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices"; Circulation: Heart Failure, 2012, 5, .	3.9	0
166	Editor's page. Journal of Thrombosis and Thrombolysis, 2014, 37, 216-216.	2.1	0
167	Measurement tools and antidotes for non-vitamin K oral anticoagulants. Journal of Thrombosis and Thrombolysis, 2016, 41, 233-233.	2.1	0
168	Reversal of Antithrombotic Therapy. JACC Basic To Translational Science, 2017, 2, 146-148.	4.1	0
169	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association, 2021, 10, e022485.	3.7	0
170	Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond. Journal of Thrombosis and Thrombolysis, 2021, 52, 408-413.	2.1	0
171	Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer. Blood, 2014, 124, 4279-4279.	1.4	0